Catalyst Pharmaceuticals Stock Price Prediction
| CPRX Stock | USD 21.02 0.15 0.72% |
Momentum 50
Impartial
Oversold | Overbought |
Quarterly Earnings Growth 0.414 | EPS Estimate Next Quarter 0.4507 | EPS Estimate Current Year 1.9738 | EPS Estimate Next Year 2.2092 | Wall Street Target Price 33.3333 |
Using Catalyst Pharmaceuticals hype-based prediction, you can estimate the value of Catalyst Pharmaceuticals from the perspective of Catalyst Pharmaceuticals response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Catalyst Pharmaceuticals using Catalyst Pharmaceuticals' stock options and short interest. It helps to benchmark the overall future attitude of investors towards Catalyst using crowd psychology based on the activity and movement of Catalyst Pharmaceuticals' stock price.
Catalyst Pharmaceuticals Short Interest
An investor who is long Catalyst Pharmaceuticals may also wish to track short interest. As short interest increases, investors should be becoming more worried about Catalyst Pharmaceuticals and may potentially protect profits, hedge Catalyst Pharmaceuticals with its derivative instruments, or be ready for some potential downside.
200 Day MA 20.034 | Short Percent 0.0634 | Short Ratio 5.95 | Shares Short Prior Month 5.4 M | 50 Day MA 22.155 |
Catalyst Pharmaceuticals Hype to Price Pattern
Investor biases related to Catalyst Pharmaceuticals' public news can be used to forecast risks associated with an investment in Catalyst. The trend in average sentiment can be used to explain how an investor holding Catalyst can time the market purely based on public headlines and social activities around Catalyst Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Some investors profit by finding stocks that are overvalued or undervalued based on market sentiment. The correlation of Catalyst Pharmaceuticals' market sentiment to its price can help taders to make decisions based on the overall investors consensus about Catalyst Pharmaceuticals.
Catalyst Pharmaceuticals Implied Volatility | 0.88 |
Catalyst Pharmaceuticals' implied volatility exposes the market's sentiment of Catalyst Pharmaceuticals stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Catalyst Pharmaceuticals' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Catalyst Pharmaceuticals stock will not fluctuate a lot when Catalyst Pharmaceuticals' options are near their expiration.
The fear of missing out, i.e., FOMO, can cause potential investors in Catalyst Pharmaceuticals to buy its stock at a price that has no basis in reality. In that case, they are not buying Catalyst because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Catalyst Pharmaceuticals after-hype prediction price | USD 21.02 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Prediction based on Rule 16 of the current Catalyst contract
Based on the Rule 16, the options market is currently suggesting that Catalyst Pharmaceuticals will have an average daily up or down price movement of about 0.055% per day over the life of the 2025-06-20 option contract. With Catalyst Pharmaceuticals trading at USD 21.02, that is roughly USD 0.0116 . If you think that the market is fully incorporating Catalyst Pharmaceuticals' daily price movement you should consider acquiring Catalyst Pharmaceuticals options at the current volatility level of 0.88%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Catalyst |
Catalyst Pharmaceuticals After-Hype Price Prediction Density Analysis
As far as predicting the price of Catalyst Pharmaceuticals at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Catalyst Pharmaceuticals or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Catalyst Pharmaceuticals, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Catalyst Pharmaceuticals Estimiated After-Hype Price Volatility
In the context of predicting Catalyst Pharmaceuticals' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Catalyst Pharmaceuticals' historical news coverage. Catalyst Pharmaceuticals' after-hype downside and upside margins for the prediction period are 17.89 and 24.15, respectively. We have considered Catalyst Pharmaceuticals' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Catalyst Pharmaceuticals is not too volatile at this time. Analysis and calculation of next after-hype price of Catalyst Pharmaceuticals is based on 3 months time horizon.
Catalyst Pharmaceuticals Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Catalyst Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Catalyst Pharmaceuticals backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Catalyst Pharmaceuticals, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.00 | 3.13 | 0.00 | 0.00 | 11 Events / Month | 12 Events / Month | In about 11 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
21.02 | 21.02 | 0.00 |
|
Catalyst Pharmaceuticals Hype Timeline
Catalyst Pharmaceuticals is currently traded for 21.02. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Catalyst is projected not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is over 100%. The immediate return on the next news is projected to be very small, whereas the daily expected return is currently at 0.0%. %. The volatility of related hype on Catalyst Pharmaceuticals is about 259.02%, with the expected price after the next announcement by competition of 21.02. About 83.0% of the company shares are held by institutions such as insurance companies. The book value of Catalyst Pharmaceuticals was currently reported as 6.02. The company had not issued any dividends in recent years. Given the investment horizon of 90 days the next projected press release will be in about 11 days. Check out Catalyst Pharmaceuticals Basic Forecasting Models to cross-verify your projections.Catalyst Pharmaceuticals Related Hype Analysis
Having access to credible news sources related to Catalyst Pharmaceuticals' direct competition is more important than ever and may enhance your ability to predict Catalyst Pharmaceuticals' future price movements. Getting to know how Catalyst Pharmaceuticals' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Catalyst Pharmaceuticals may potentially react to the hype associated with one of its peers.
Catalyst Pharmaceuticals Additional Predictive Modules
Most predictive techniques to examine Catalyst price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Catalyst using various technical indicators. When you analyze Catalyst charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Catalyst Pharmaceuticals Predictive Indicators
The successful prediction of Catalyst Pharmaceuticals stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Catalyst Pharmaceuticals, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Catalyst Pharmaceuticals based on analysis of Catalyst Pharmaceuticals hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Catalyst Pharmaceuticals's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Catalyst Pharmaceuticals's related companies. | 2022 | 2023 | 2024 | 2025 (projected) | Days Sales Outstanding | 17.79 | 49.05 | 48.6 | 45.35 | PTB Ratio | 6.4 | 4.61 | 3.4 | 3.23 |
Story Coverage note for Catalyst Pharmaceuticals
The number of cover stories for Catalyst Pharmaceuticals depends on current market conditions and Catalyst Pharmaceuticals' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Catalyst Pharmaceuticals is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Catalyst Pharmaceuticals' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Catalyst Pharmaceuticals Short Properties
Catalyst Pharmaceuticals' future price predictability will typically decrease when Catalyst Pharmaceuticals' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Catalyst Pharmaceuticals often depends not only on the future outlook of the potential Catalyst Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Catalyst Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 124.9 M | |
| Cash And Short Term Investments | 517.6 M |
Additional Tools for Catalyst Stock Analysis
When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.